Hera BioLabs – implementation of Precision Toxicology
Samplify Bio – DNA Collection Made Simple
Biomere – preclinical CRO
Sekisui XenoTech Provides Pooled Human Liver Homogenate for Evaluation of Drug Metabolizing Enzymes and Proteins
Creative Bioarray – Cells and Tissue Arrays
Aduro Biotech is a clinical-stage cancer immunotherapy company with multiple therapeutic approaches in development that have the potential to yield powerful immunotherapy combinations.
Aduro Biotech – engineered Immunotherapy for Cancer
Anton Paar develops, produces and distributes highly accurate laboratory instruments and process measuring systems, and provides custom-tailored automation and robotic solutions. It is the world leader in the measurement of density, concentration and CO2 and in the field of rheometry. The core competence of Anton Paar – high-precision production – and close contact to the scientific community form the basis for the quality of Anton Paar’s instruments.
Anton Paar – process measuring systems
Worthington Biochemical – high quality enzymes
Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases.
Bavarian Nordic – poxviral-based vaccine
Bavarian Nordic has built its foundation around two poxviral-based vaccine platform technologies, Modified Vaccinia Ankara – Bavarian Nordic (MVA-BN) and Vaccinia-Fowlpox-TRICOM (VF-TRICOM) that have the potential to support a broad product pipeline in both infectious diseases and cancer immunotherapies. Both technologies can be manufactured at commercial scale at Bavarian Nordic’s own facility, which was recently expanded to accommodate the production of multiple products. Bavarian Nordic focuses on developing product candidates to address cancer and infectious diseases by leveraging several core strengths:
- Extensive R&D expertise in vaccines and immunotherapy
- Broadly applicable platform technology
- Multiple clinical stage development programs, including two Phase 3 trials
- Flexible, commercial scale manufacturing facility
- Significant financial resources resulting from IMVAMUNE supply contracts and government-funded R&D programs
Through a long-standing collaboration with the U.S. Government, Bavarian Nordic has developed a portfolio of biological countermeasures, including the non-replicating smallpox vaccine, IMVAMUNE, which is stockpiled for emergency use by the U.S. and other governments. The vaccine is approved in the EU (under the trade name IMVANEX) and in Canada. Bavarian Nordic and its partner Janssen are pioneering the development of an Ebola vaccine, which has been fast-tracked by authorities in response to the current situation in West Africa. Additionally, in collaboration with the National Cancer Institute, Bavarian Nordic has developed a portfolio of active cancer immunotherapies based on its versatile pox-virus based technologies, including PROSTVAC, which is currently in Phase 3 clinical development for the treatment of advanced prostate cancer. The company has partnered with Bristol-Myers Squibb for the potential commercialization of PROSTVAC.
Bavarian Nordic is a biotech company headquartered in Denmark, Germany and USA. Bavarian Nordic’s shares are listed on Nasdaq Copenhagen under the symbol BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored Level 1 ADR program listed in the US (OTC) under the symbol BVNRY.
More about Bavarian Nordic : www.bavarian-nordic.com